Global | en Contact
Mission

Striking the Balance between Innovative and Affordable Medicines

Minapharm has made its mission to provide patients in developing countries with easy access to innovative and high-quality medicines. Minapharm’s expertise encompasses a wide range of medicines, from small molecules with advanced galenic formulation to more complex bioengineered proteins.

Learn More
Science

Driving Innovation in Advanced Life Sciences to Develop Cutting-Edge Technologies, Medicines, and Vaccines

Minapharm develops, manufactures and commercializes over 150 lifesaving and life-enhancing products, ranging from small molecules to complex genetically engineered proteins. The company also offers an impressive portfolio of proprietary technologies used by the global biotech industry at large.

Scientific Portfolio
...
Small Molecules

A unique portfolio of first to launch and advanced galenic formulations.

Small Molecules
...
Recombinant Proteins

Minapharm’s self-developed first and second generation biologics portfolio.

Recombinant Proteins
...
Cell & Gene Therapy

The first CGT products in the region using our proprietary technologies.

Cell & Gene Therapy
Innovative Technologies
...
Proprietary technologies

Intelligent biopharmaceutical solutions for the biotech industry at large.

Proprietary technologies
...
Process Development

State-of-the-art technologies for the production of biological APIs.

Process Development
...
Manufacturing technologies

Latest end-to-end manufacturing technologies for biological drug substances.

Manufacturing technologies
Learn more
smallmol-on-purple smallmol-on-purple
Global Outreach

Crossing International Borders and Scientific Boundaries with Minapharm's Unique Strategic Business Model and Proprietary Technologies

Mianpharm is the only gene-to-market company in Africa and the Middle East providing advanced proprietary technologies to the global biotech industry coupled with end-to-end manufacturing and commercialization expertise for many decades.

...
Subsidiaries
.
Three International subsidiaries headquartered in Cairo and Berlin
...
Manufacturing Sites
.
Six cutting-edge inter-continental manufacturing sites for biological drug substance, biological drug product, and small molecules
...
Business Partnerships
.
Longstanding global and regional business partnerships
Africa & The Middle East

Committed to the Transformation of Healthcare on the African Continent and
the Middle East Region

Minapharm takes a regional approach to affecting global change. Together with its global subsidiary MiGenTra GmbH, Minapharm has a core mission to satisfy the unmet medical needs of patients in Africa and the Middle East.

...
Small Molecules
.
Small Molecules
...
Biosimilars
.
Biosimilars
...
Vaccines
.
Vaccines
...
Cell and Gene Therapies
.
Cell and Gene Therapies
Learn More
Africa
Making Headlines

Stay Up to Date with the Latest Developments at Minapharm

Minapharm Announces the Appointment of Dr. Alfred Merz, PhD as COO and Interim CEO of its Berlin-Based Subsidiary ProBioGen AG

Cairo, Berlin – May 30, 2024 - Minapharm, the leading pharmaceutical and biopharmaceutical company in Egypt, Africa, and the Middle East announced on May 30th, the appointment of Dr. Alfred Merz, PhD as the new COO and interim CEO of its Berlin-based subsidiary ProBioGen AG, a world leading Contract Development and Manufacturing Organization (CDMO) and technology provider with expertise in cell line engineering, process development, and GMP manufacturing.

  • 30/05/2024
Minapharm Pharmaceuticals and Cheerland Biotechnology Sign a Memorandum of Understanding towards a Strategic Partnership in the MEA Region and Asia

Cairo, Egypt – Shenzhen, China -- Dec 21.12.2023

Minapharm Pharmaceuticals, a premier biopharmaceutical company in the Middle East and Africa and global provider of proprietary technologies, headquartered in Egypt with multiple global subsidiaries, and Cheerland Biotechnology (CLB), a global biologics contract development and manufacturing organization based in China, today, December 21st, 2023, announced the signing of a Memorandum of Understanding (MoU) with the aim of jointly pursuing potential business opportunities in the MEA region and Asia.

  • 21/12/2023
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane®

Sanofi and Minapharm announce the signing of an exclusive Manufacturing and Supply Agreement for the localization of the full range of its flagship market leader product, Clexane®.

The agreement between Sanofi, a global pharmaceutical company and Egypt’s Minapharm, a regional Biotech company with wholly owned subsidiaries in Cairo and Berlin, boosts Egypt’s national localization strategy of biopharmaceutical manufacturing.

  • 05/12/2023
Learn More